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Abstract
Summary: The AptaBlocks Web Interface is focused on providing
graphical, intuitive, and platform independent access to AptaBlocks, an
experimentally validated algorithmic approach for the in-silico design of
oligonucleotide sticky bridges. The availability of AptaBlocks online to
the nucleic acid research community at large makes this software a highly
effective tool for accelerating the design and development of novel oligonu-
cleotide based drugs and other biotechnologies.
Availability: The AptaBlocks Web Interface is freely available at
www.ncbi.nlm.nih.gov/CBBresearch/Przytycka/index.cgi#aptablocks
1 Introduction
Oligonucleotides are rapidly emerging as competitive and highly efficient
alternatives to traditional therapeutics and are increasingly employed in a
growing array of biotechnological applications [1, 2, 3, 4]. These include,
but not limited to next-generation biosensors [5, 6, 7] and, more recently,
in in vitro and in vivo delivery systems for individualized medicine ap-
proaches which frequently face the challenge of delivering a drug across a
biological membrane to reach their target.
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A large number of these technologies rely on a multi-stage architecture
in which several biomolecules are combined together to form a biologically
functional unit. Personalized drug therapy particularly benefits from such
a modular model as these approaches typically consist of a case-specific
and exchangeable delivery molecule joint with a target-specific therapeu-
tic.
While designing a molecule to cross a particular membrane has proven
challenging, aptamers, small RNA or DNA molecules explicitly designed
to bind a target of interest with high specificity and affinity, have estab-
lished themselves as a prominent choice for this task. As a case in point,
one of the earlier approaches successfully created a cell internalizing deliv-
ery system in vitro by coupling an anti-prostate specific membrane antigen
aptamer with an anti-Lamin A/C siRNA for the inhibition of gene expres-
sion [8]. More recently, in vivo, prostate cancer cells expressing prostate-
specific membrane antigen (PSMA) have been successfully targeted with
optimized aptamer-siRNA chimeras resulting in pronounced regression of
PSMA-expressing tumors in athymic mice after systemic administration
[9]. In addition, an aptamer-cargo conjugate is currently being assessed
as a targeted delivery system for pancreatic cancer in vivo [10].
The success of the above mentioned approaches hinges on the ability
to effectively conjugate the delivery agent with the cargo. While previous
generations of oligo-cargo complexes have relied on conjugation techniques
such as streptavidin based bridges and similar methods [8], more recent
approaches have opted for a more flexible nucleotide hybridization tech-
nique. This so called sticky bridge approach consists of two short and
complementary sequence strands which are covalently bound to the deliv-
ery and cargo oligonucleotide respectively and are expected to hybridize,
hence forming the desired complex in solution.
The specific sequence of such bridges however must be carefully de-
signed such that its stands do not interact with neither the delivery com-
ponent nor the therapeutic as to form undesired dimers. This process has
traditionally been a laborious and costly trail-and-error process involving
the synthesis of an initial sticky bridge based on personal expertise, fol-
lowed by experimental testing for hybridization, subsequent fine-tuning
of the sequence, and iteration of these steps until the desired binding
strength and stability of the complex is achieved.
To improve this process, and to accelerate the design of RNA-based
drug delivery systems, we recently developed AptaBlocks [11], a compu-
tational method to design optimized sticky bridges while minimizing the
probability of undesired dimer formation (see Supplementary Section 2).
While the utility of AptaBlocks for novel, mutli-component oligothera-
pies is clearly evident, our program is currently available as a command
line interface (CLI) tool only, possibly restricting its accessibility to the
broader biotechnology community.
Here, we present the AptaBlocks Web Interface, a fully featured, plat-
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form independent version of AptaBlocks that can be accessed from any
web browser. In contrast to its CLI counterpart, the AptaBlocks Web
Interface guides the user through an intuitive, graphical step-by-step pro-
cess allowing for the generation of sticky bridges that are optimized for
up to five cargoes simultaneously.
2 Web Server
The web server is partitioned into two parts dedicated to parameter input
and results presentation. In what follows, we provide a brief overview of
the structure and functionality of these segments.
Parameter Input: The AptaBlocks Web Interface consists of two
main sections for the exploration of sticky bridges. The first section al-
lows the user to retrieve any previous jobs from the server by entering
the unique id number assigned to every new job and provided to the user
upon submission. Depending on the validity of the job id, the user will
either be informed that no such job exists, or is presented with the re-
sults screen as detailed in the Results Section. Alternatively, should the
corresponding job still be running, the user is presented with a waiting
screen displaying the job id, the status of the job (i.e. queued, running,
completed, or failed), and the elapsed time on the server since submission
in seconds.
The second section allows for the design of a new sticky bridge with one
delivery oligonucleotide (First Molecule) and up to five cargoes (Second
Molecules) as shown in Figure 1. Each cargo is given a unique identifier
for later differentiation.
The AptaBlocks Web Interface requires an initial sticky bridge se-
quence to optimize which can consist of an educated guess or a random
sequence of desired length (e.g. ’GAUCGA’ for a 6nt sticky bridge). A
non-default value in the range of 1 to 10 for Lambda, the parameter con-
trolling the trade-off between the binding strength of the sticky bridge
and structure preservation of the molecules, can be entered. The larger
this value, the more weight is put on the sticky bridge strength during the
optimization process.
Next, the properties of the first molecule can be defined. First, the
location of the sticky bridge on the oligo strand is selected which can
either be positioned on the five prime end, the three primer end, or some-
where in the center of the sequence. Depending on this choice the user is
prompted to provide the oligo sequence located upstream, downstream, or
on both sides of the sticky bridge. In addition, the number of desired 3C
spacers, between the oligo and the sticky bridge can be defined for each
of the selected sequences. These elements consist of one or more three-
carbon molecules that are used to incorporate a short spacer arm into an
oligonucleotide and computationally treated as incapable of pairing with
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Figure 1: Screen capture of the AptaBlocks Web Interface. Shown are exem-
plary values for the different parameters a user is guided through in order to
design an optimal sticky bridge for the desired input oligos. Each option is ac-
companied with a detailed description regarding the requirement and purpose of
this property. In addition, the user is presented with a preview of the complex
in real time. 4
any nucleotide.
The options for the second molecule(s) are analogous to that of the
first one with the additional ability to select the cargo sequence to be ei-
ther single stranded (ssRNA) or double stranded (dsRNA). Furthermore,
up to five molecules can be configured to be optimized simultaneously
through the ”Add Oligo” button.
Finally, for each of the delivery-cargo complexes, a live preview of the
complex is created in order to provide the user with a visual aid of the
molecule to be optimized.
The Results Section: Upon completion of the optimization process
with AptaBlocks, or upon retrieval of a previously completed job, the
optimized sticky bridge sequence is presented to the user along with a
summary of the parameter chosen on the initial submission form. For
each of the second molecules, the probability of preserving the structure
of the delivery oligo, the probability of preserving the structure of the
cargo, the probability of forming undesired dimers, as well as the free en-
ergy of the sticky bridge is presented to the user. A visual preview of the
corresponding delivery-cargo complex is also provided.
3 Conclusion
A multitude of current and future nucleic acid based, personalized drug
therapies as well as other biomedical approaches such as next-generation
biosensors require the formation of molecular complexes from two or more
oligonucleotides in order to perform their intended action. Finding the
specific nucleotide sequence to effectively link the individual components
together via sticky bridges has traditionally remained a tedious, wet-lab
based task that is very much dependent on personal expertise. This pro-
cess has recently been complemented with a systematic, computational
approach that significantly streamlines and accelerates the design of the
sticky bridge and adds the ability optimize the latter to be compatible
with a multitude of molecules. This tool, known as AptaBlocks, however
has until now only been available in command line form, possibly limit-
ing its availability to the extended nucleic acid research community. The
AptaBlocks Web Interface closes this gap by providing AptaBlocks online
though a distributed, high-availability computation grid with an appro-
priate graphical interface that is not only platform independent, but also
intuitive and highly user friendly to use.
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